Forwardly’s Ligand Innovation Global Receives Significant Designations Under the Patent Cooperation Treaty
Forwardly, Inc. (OTCMKT: FORW) partner Ligand Innovation Global has received crucial designations for its LifeAir G1 Portable Ventilator under the Patent Cooperation Treaty (PCT). The International Preliminary Examining Authority confirmed the device's novelty, inventiveness, and industrial applicability. This advancement positions the ventilator as an economical solution for hospitals during emergencies. Ligand aims to provide affordable units to medical facilities, enhancing response to respiratory crises.
- Ligand's LifeAir G1 Portable Ventilator recognized for novelty, inventiveness, and industrial applicability by the International Preliminary Examining Authority.
- Potential for the LifeAir G1 to provide a cost-effective solution for emergency medical situations.
- None.
Mississauga, ON and Henderson, NV, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Dr. Dayo Olakulehin, CEO of Ligand Innovation Global, Inc., (“Ligand”) a partially owned company and partner of Forwardly, Inc. (OTCMKT: FORW), announced today that Ligand has received important designations under the Patent Cooperation Treaty (“PCT”).
In a written opinion of the International Preliminary Examining Authority (“IPEA”), Ligand’s LifeAir G1 Portable Ventilator was found to be (a) Novel, (b) Inventive; and (c) Industrially Applicable.
The (PCT) makes it possible to seek patent protection for an invention simultaneously in each of a large number of countries by filing an "international" patent application. Such an application may be filed by anyone who is a national or resident of a PCT Contracting State. It may generally be filed with the national patent office of the Contracting State of which the applicant is a national or resident or, at the applicant's option, with the International Bureau of World International Property Organization in Geneva. Ligand’s application was filed through the Canadian Intellectual Property Office.
Forwardly’s Medical Board of Advisors member, Dr. Michael Soffer, stated, “I have long believed that Dr. Olakulehin’s concept for a portable ventilator was unique and the IPEA has now confirmed my opinion. Ligand is well on its way to providing an efficient and economical device to aid in the battle against the current pandemic and other threats to patients’ respiratory system.” Dr. Soffer participates in weekly reviews of the project’s development and progress. His credentials as a Board Certified Diplomate of the National Board of Medical Examiners, the American Board of Internal Medicine, and the American Board of Pulmonary Diseases, are particularly valuable to both Forwardly and Ligand.
About Ligand Innovation Global, Inc.
Ligand IG continues development of the LifeAir G1 Emergency Portable Ventilator to address the expense of conventional ventilator systems which require the intubation and sedation of the patient. Ligand IG expects these units to become readily available, at a greatly reduced cost, to hospitals, nursing homes, and other sites where emergency, life-saving equipment, such as defibrillators are a necessity. Additional information regarding Ligand IG can be found at www.LigandGlobal.com.
About Forwardly, Inc.
Forwardly is an opportunity investor seeking to partner in fresh ideas. The company is headed by George Sharp, a longtime whistleblower, advocate against microcap fraud, and defender of shareholder rights. In addition to his continued participation in these activities, Mr. Sharp consults to public companies, attorneys and those associated with the financial markets. He is also a former consultant to OTC Markets Group, Inc. Further information about Forwardly, Inc. can be obtained through its website at www.ForwardlyPlaced.com
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACT:
Forwardly, Inc.
3535 Executive Terminal Drive
Suite 110
Henderson, NV 89052
702-840-4433
FAQ
What designations did Forwardly partner Ligand receive for the LifeAir G1 Portable Ventilator?
How does the LifeAir G1 Portable Ventilator benefit medical facilities?
What is Forwardly, Inc.'s role in the development of the LifeAir G1 Portable Ventilator?
When was the press release about the LifeAir G1 Portable Ventilator issued?
What does the Patent Cooperation Treaty (PCT) allow for companies like Ligand?
